OraSure Reports First Profit in Years Amid Operational Improvements but Faces Growth Challenges
OraSure Technologies (NASDAQ:OSUR) reported a return to profitability for the first time in years, with GAAP net income of $6.2 million during Q2 2026 compared to a loss of $19.7 million in the same period last year. Revenue rose by 9.7% from the prior quarter and beat guidance at $30.6 million. Operational improvements included expanded gross margins, regulatory wins for its diagnostic products, and reduced cash burn over six months. However, much of this profit stemmed not from core business performance but rather a one-time accounting adjustment related to an updated submission plan for OraSure’s CT/NG test on the Sherlock platform. Excluding that gain, non-GAAP operating losses widened slightly year-over-year. The company also faced delays in its InteliQuick CT/NG molecular self-test due to FDA feedback. Despite some positive operational signs and regulatory approvals, revenue growth remains flat or declining when excluding pandemic-related testing categories like Risk Assessment Testing. Institutional interest has increased modestly with 20 hedge funds now holding shares.
Tickers: $RHHBY
Topics: profitability regulatory_clearance revenue_growth stock_buybacks